The effect of postmastectomy radiotherapy on patient-reported outcomes

Affiliations

¹ Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada; Department of Radiation Oncology, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. Electronic address: eileen.rakovitch@sunnybrook.ca.
² Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada; Department of Radiation Oncology, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.

Comment

Eileen Rakovitch et al. Lancet Oncol. 2018 Nov.

. 2018 Nov;19(11):1429-1431.

doi: 10.1016/S1470-2045(18)30586-2. Epub 2018 Oct 15.

¹ Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada; Department of Radiation Oncology, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. Electronic address: eileen.rakovitch@sunnybrook.ca.
² Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada; Department of Radiation Oncology, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.

No abstract available

Comment on

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell NS; MRC SUPREMO trial UK investigators. Velikova G, et al. Lancet Oncol. 2018 Nov;19(11):1516-1529. doi: 10.1016/S1470-2045(18)30515-1. Epub 2018 Oct 15. Lancet Oncol. 2018. PMID: 30337220 Clinical Trial.